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Abstract
Converging evidence increasingly implicates shared etiologic and pathophysiological characteristics among major
psychiatric disorders (MPDs), such as schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD).
Examining the neurobiology of the psychotic-affective spectrum may greatly advance biological determination of
psychiatric diagnosis, which is critical for the development of more effective treatments. In this study, ensemble clustering
was developed to identify subtypes within a trans-diagnostic sample of MPDs. Whole brain amplitude of low-frequency
ﬂuctuations (ALFF) was used to extract the low-dimensional features for clustering in a total of 944 participants: 581
psychiatric patients (193 with SZ, 171 with BD, and 217 with MDD) and 363 healthy controls (HC). We identiﬁed two
subtypes with differentiating patterns of functional imbalance between frontal and posterior brain regions, as compared to
HC: (1) Archetypal MPDs (60% of MPDs) had increased frontal and decreased posterior ALFF, and decreased cortical
thickness and white matter integrity in multiple brain regions that were associated with increased polygenic risk scores and
enriched risk gene expression in brain tissues; (2) Atypical MPDs (40% of MPDs) had decreased frontal and increased
posterior ALFF with no associated alterations in validity measures. Medicated Archetypal MPDs had lower symptom
severity than their unmedicated counterparts; whereas medicated and unmedicated Atypical MPDs had no differences in
symptom scores. Our ﬁndings suggest that frontal versus posterior functional imbalance as measured by ALFF is a novel
putative trans-diagnostic biomarker differentiating subtypes of MPDs that could have implications for precision medicine.
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Deﬁnitive biomarkers have remained elusive in psychiatry,
while other ﬁelds of medicine have amassed an armory of
biomarkers for diagnosis and treatment. This is not entirely
surprising as studies have primarily utilized nosology that
differentiates neuropsychiatric disorders based on clinical
phenomenology in the absence of any biological determinant, albeit the Diagnostic and Statistical Manual of Mental
Disorders (DSM) has revolutionized the ﬁeld and advanced
it to its current state. Long conceptualized as distinct
diagnostic categories, major psychiatric disorders (MPDs),
consisting of schizophrenia (SZ), bipolar disorder (BD), and
major depressive disorder (MDD), share substantial core
features as implicated by converging lines of evidence from
genetic, molecular, histological, and neuroimaging studies
[1–6]. Thus, there appears to be a greater continuum
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between psychotic and affective disorders than previously
thought. Consequently, understanding the core changes in
MPDs is critical for mapping the principal neural pathways
resulting in psychopathology and the crossroads at which
divergent paths lead to varying clinical phenomenology
within and across diagnoses.
Several studies have adopted alternative approaches to
identifying brain-based biomarkers that transcend traditional diagnostic boundaries [7, 8]. Recently, Clementz
et al. conducted a k-means clustering analysis of cognitive
and electrophysiological measures using trans-diagnostic
data generated from the Bipolar-Schizophrenia Network for
Intermediate Phenotype consortium [7]. They identiﬁed
three “biotypes” that were largely orthogonal to the DSMIV diagnoses and signiﬁcantly different with respect to
external validating measures such as brain structure and
function [9, 10]. Their approach has been touted as an
important step toward a more neurobiologically based
understanding of psychosis [11]. Subsequently, pioneering
work by Drysdale et al. identiﬁed four biotypes in depression using canonical correlation analysis of the Hamilton
Depression Rating Scale (HAMD) to characterize connectivity features [8]. Their work presented yet another
strategy for reﬁning classiﬁcation within clinically heterogeneous diagnoses, as well as identifying individuals who
may be more responsive to transcranial magnetic
stimulation.
Neuroimaging has offered a wealth of potential biomarkers for neuropsychiatric disorders. Abnormal brain
function has been proven to be useful in the assessment of
pain [12] and shows great promise for application to
neuropsychiatric illnesses. Resting-state functional magnetic resonance imaging is well-established and has been
widely performed for noninvasive exploration of the
brain’s intrinsic functional architecture using measurements of spontaneous low-frequency ﬂuctuations (LFFs)
in the blood oxygenation level-dependent (BOLD) signal
[13, 14]. Although their underlying mechanism is not
exactly clear, LFFs appear to arise from neurovascular
activity [15] and have been associated with glutamatergic/
GABAergic synaptic currents and glial activity [16, 17].
Furthermore, the amplitude of BOLD signal ﬂuctuations
is proportional to regional cerebral blood ﬂow, which is
an established marker of brain metabolic activity [18].
The amplitude of low-frequency ﬂuctuations (ALFF;
generally in the range of 0.01–0.08 Hz) appears to be an
efﬁcient index of local spontaneous neuronal activity at
rest [19]. Regional variability in ALFF reﬂects spontaneous ﬂuctuations in a given voxel independent of its
neighboring, regional, or network connectivity. Moreover,
ALFF exhibits moderate to substantial test-retest reliability [20] ensuring a high upper bound for its validity as a
regional functional measure to detect individual
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differences [21]. Prior studies, including a multi-center
study and our previous work, have shown signiﬁcant
alterations in ALFF across MPDs compared to healthy
controls (HC), most prominently in frontal, subcortical,
and temporal regions, as well as in visual regions (precuneus and cuneus); however, inconsistencies have been
reported [6, 22, 23].
In this study, we present a novel clustering method utilizing deep learning to identify subtypes across the
psychotic-affective disorder spectrum in a trans-diagnostic
sample of MPDs. We used a deep stacked AutoEncoder to
extract low-dimensional features of ALFF followed by an
ensemble clustering method to identify ALFF-based subtypes that were maximally dissimilar from each other in
MPDs. We then validated the resulting subtypes using
cortical thickness, white matter integrity as measured by
fractional anisotropy (FA), polygenic risk scores (PRS), and
risk gene expression tissue proﬁle. We also examined the
effects of medication status on symptom severity to elucidate possible pharmacologic effects within each of the
subtypes.

Methods
Samples and measures
The study included a total of 944 participants consisting of
581 patients with MPDs (193 with SZ, 171 with BD, 217
with MDD) and 363 HC, who were recruited and scanned at
a single site with identical inclusion and exclusion criteria.
MPD participants were recruited from the inpatient and
outpatient services at Shenyang Mental Health Center and
Department of Psychiatry, The First Afﬁliated Hospital of
China Medical University, Shenyang, China. HC participants were recruited from the local community by advertisement. Behavioral symptoms were assessed using the
HAMD and Brief Psychiatric Rating Scale (BPRS). Cognitive function was assessed using the Wisconsin Card
Sorting Test (WCST). Demographic and clinical characteristics are detailed in Supplementary Tables 1 and 2.
Whole blood samples (243 patients and 193 HC) were
collected. All participants provided written informed consent after receiving a detailed description of the study. The
study was approved by the Institutional Review Board of
China Medical University.
Functional MRI, structural MRI, and diffusion tensor
imaging (DTI) were acquired in a GE Signa HD 3.0T
scanner with a standard 8-channel head coil at the First
Afﬁliated Hospital of China Medical University, Shenyang,
China. Functional images were collected with a gradient
echo planar imaging (EPI) sequence for ALFF measures.
Three-dimensional, high-resolution, T1-weighted images
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were collected using a 3-D fast spoiled gradient echo
sequence to measure cortical thickness. DTI used a singleshort spin-EPI sequence to measure FA for assessing white
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matter integrity. For all scanning sequence parameters and
image preprocessing, please see “Methods” in the Supplementary information.
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Fig. 1 Schematic of using deep learning-based hierarchical clustering to deﬁne clusters of MPDs. Step one: identiﬁcation of signiﬁcant functional alterations in MPDs and using AutoEncoder to
reduce the dimension of the identiﬁed alterations to d ∈ [2,10]. Step
two: for each of the nine low-dimensional data from step one, we
obtained nine different class labels based on clustering analyses, and
ﬁve clusters (cluster A, B, C, D, and E) were identiﬁed. Step three: we
performed the clusters merging process according to six runs of
clustering and obtained two ﬁnal subtypes. Furthermore, the subtypes
varied in patterns of amplitude of low-frequency ﬂuctuation alterations
as compared to HC (voxel p < 0.001 with Gaussian random ﬁeld
correction for cluster p < 0.05). MPD major psychiatric disorder; HC
healthy control; L left; R right; d dimension.

described above into a low-dimensional representation
consisting of nine layers with sizes 2175-2048-1024-512256-128-64-32-d and the symmetrical reconstruction by the
decoder as the output. Mean square error was used as the
loss function to minimize the differences between the input
of 2175 voxels and the reconstructed voxels at the output
layer. Compared to the conventional dimensionality
reduction methods such as principal component analysis,
AutoEncoder is capable of learning intrinsic, nonlinear
relationships in the input data and therefore better suited for
high-dimensional nonlinear data [25].

Genotyping, imputation and calculation of PRS, and risk
gene expression were also performed. Details about how
they were performed can be found in “Methods” in the
Supplementary information.

Step two: ensemble clustering

Ensemble clustering method based on deep
learning
Clustering algorithms group data points (i.e., participants)
based on their similarity in dimensional space. For highdimensional data, such as whole brain ALFF, the number of
dimensions must be reduced to avoid the “curse of dimensionality” [24]. Consequently, clustering results are dependent
on the dimensional representation selected for analyses;
however, there is no established standard for selecting an
appropriate dimensional representation. Thus, our algorithm
was designed to perform clustering analyses for multiple
dimensional representations and then use consensus group
assignment followed by a robustness optimization protocol to
achieve the most reliable and stable subtype assignment.
Subtypes were identiﬁed in n = 581 patients with MPDs
using a novel ensemble clustering method based on deep
stacked AutoEncoder in the following steps (Fig. 1).

A common problem of clustering high-dimensional data is
that inappropriate low-dimensional representations of data
will lead to unreliable clustering results. To avoid this
problem, we designed a new ensemble method to integrate
hierarchical clustering results from multiple d-dimensional
representations (d ∈ [2, 10]) (Supplementary Fig. 1) which
obtained from the autoencoder. The Euclidean distance was
used to compute the distance between participants and the
complete linkage method was used to compute the distance
between clusters. For each d-dimensional representation
(d ∈ [2, 10]), we obtained a set of clustering results for all
participants. Therefore, each participant was subsequently
assigned nine class labels, one for each of the clustering
result based on nine d-dimensional representations. A
consensus was determined by the majority of the nine class
labels and served as the cluster assignment for each participant. Therefore, the ensembled result can better reﬂect the
inherent clustering characteristics of the data, because it
integrates the results from multiple low-dimensional representations of participants.
Step three: optimization of clustering robustness

Step one: dimension reduction
To identify principal ALFF alterations, we extracted voxels
with signiﬁcantly different ALFF between MPDs and HC
using a general linear model (GLM). For GLM analyses,
gender (male/female) and group (MPDs/HC) were included
as discrete factors and age as a continuous factor, and the
effect of group on ALFF was the primary interest of the
analysis. The signiﬁcance level was set at voxel p < 0.001
with the Gaussian random ﬁeld (GRF) correction for cluster
p < 0.05. A total of 2175 voxels were identiﬁed as signiﬁcantly different in ALFF between MPDs and HC from
the whole brain of 42,185 voxels. We then used AutoEncoder [25], a deep artiﬁcial neural network, to further
reduce the dimensions of the input data to d ∈ [2, 10].
AutoEncoder included an encoder and a symmetric decoder.
The encoder compressed the 2175 voxels obtained as

While the ensemble clustering method was effective, it was
relatively sensitive to the low-dimensional representations
obtained from the autoencoder. To improve the robustness of
the clustering results, we merged some clusters based on
multiple runs of the clustering method. To this end, we ﬁrst
introduced a new index to quantify the robustness of a cluster.
The robustness index Ri of cluster i was calculated as
j\ C j j

Ri ¼ j ∪j Cij j, where Cij is the j-th run of the clustering method on
j

i

cluster i. A larger robustness index Ri means a more stable
cluster i. We then adopted an iterative, hierarchical scheme to
merge clusters with low robustness. Speciﬁcally, we iteratively
combined the two clusters with the lowest robustness indices
until all clusters were robust enough, i.e., their robustness
indices were greater than a threshold δ. In our analysis, δ was
set to 0.8 based on our experiment on the brain image data.
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Subtype-related validation across multi-level
biological data

Clinical diagnosis-related validation across multilevel biological data

Comparison of ALFF alterations with HC

We also performed analogous analyses on ALFF, cortical
thickness, white matter integrity, PRS, risk gene expression,
and effects of medication status based on clinical diagnosis.

Group comparisons of ALFF values were performed by
DPABI [26]. For each voxel, GLM was performed to
examine the difference in ALFF between each subtype and
HC. For GLM analyses, gender and group were included as
discrete factors and age as a continuous factor, and the
effect of group on ALFF was of primary interest. Statistical
signiﬁcance was determined by combining individual voxel
p (uncorrected) < 0.001 with GRF correction for clusterlevel inference of p < 0.05.
Cortical thickness and white matter integrity
Group comparisons of cortical thickness were performed
vertex-wise on the cortical surface by Freesurfer
(MRI_glmﬁt), and FA values were calculated in SPM8
(http://www.ﬁl.ion.ucl.ac.uk/spm). For each vertex or
voxel, GLM was used to examine differences in cortical
thickness and FA between each subtype and HC. GLM
design and statistical signiﬁcance were the same as those in
ALFF analyses.
Genetic loading analysis
Association of PRS (PRS-SZBD and PRS-MDD) with each
subtype was performed with logistic regression, and
Nagelkerke’s pseudo-R2 was calculated to measure the
proportion of variance explained. We estimated and analyzed high-resolution PRS at 105 different levels of PT
(ranging from 0 to 0.5 with increments of 0.005 plus 10−6,
10−5, 10−4, 0.001, and 1). To correct for multiple comparison, a signiﬁcance threshold of p = 0.004 was adopted as
suggested by Euesden et al. [27].
Clinical and cognitive measures
Two-sample t-tests were used to examine differences in
HAMD and BPRS total and factor scores and WCST
scores between subtypes. Statistical signiﬁcance was set at
p < 0.05 with FDR correction for multiple comparisons.
HAMD and BPRS factor scores were identiﬁed
from exploratory factor analysis using the principal
component factor method in MPDs (n = 581) (“Methods”
in Supplementary information, Supplementary Tables 3
and 4). Subsequently, the resulting HAMD and
BPRS factors were used in a group analysis where we
performed two-sample t-tests (p < 0.05 with FDR correction) to examine the effects of medication status for each
subtype.

Results
Identiﬁed subtypes and relation to clinical
diagnoses
The novel ensemble clustering method identiﬁed two subtypes in the MPDs sample (n = 581), Archetypal MPDs
(cluster A, 60% of the MPDs sample) and Atypical MPDs
(Fig. 1 and Supplementary Table 5). The distribution of
clinical diagnosis (SZ, BD, and MDD) varied between
Archetypal and Atypical MPDs. A greater proportion of SZ
appeared in Archetypal MPDs (40%) than Atypical MPDs
(16%). BD and MDD represented 27% and 33%, respectively, in Archetypal MPDs and 35% and 49%, respectively,
in Atypical MPDs (Supplementary Fig. 2a). From the perspective of clinical diagnoses, there were more SZ belong to
Archetypal MPDs (86%). While the proportion of BD and
MDD subtyped as Archetypal MPDs were relatively smaller
(65 and 61%, respectively), BD and MDD comprised much
larger portions of Atypical MPDs than SZ. 86% of SZ were
subtyped asArchetypal Mods (Supplementary Fig. 2b).

Subtype-related characteristics
Subtype-related ALFF alterations
In Archetypal MPDs (n = 411), ALFF was signiﬁcantly
increased in frontal areas (prefrontal cortex, limbic, paralimbic, and striatum) and signiﬁcantly decreased in posterior areas (primary sensory and motor cortices and unimodal
association cortices), compared to HC (n = 363) (Cohen’s
d = 0.64, p < 0.001) (Subtypes deﬁnition in Fig. 1). The
converse was observed in Atypical MPDs (n = 170): ALFF
was signiﬁcantly decreased in frontal areas (prefrontal
cortex, limbic, paralimbic, and striatum), and was signiﬁcantly increased in posterior areas (primary sensory and
motor cortices and unimodal association cortices), compared to HC (n = 363) (Cohen’s d = 0.43, p < 0.001)
(Subtypes deﬁnition in Fig. 1).
Subtype-related cortical thickness and white matter
integrity
In Archetypal MPDs, cortical thickness (n = 377) and FA
values (n = 397) were signiﬁcantly decreased in multiple
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Fig. 2 Signiﬁcant differences
in (a) cortical thickness and (b)
white matter integrity between
Archetypal MPDs and healthy
controls. Signiﬁcance level was
set to voxel p < 0.001 with
Gaussian random ﬁeld
correction for cluster p < 0.05.
The color bar represents t value.
MPD major psychiatric disorder.
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brain regions compared to HC (n = 353 and 359) (cortical
thickness: Cohen’ d = 0.28; p = 0.002. FA values: Cohen’
d = 0.52; p < 0.001) (Fig. 2). In Atypical MPDs, no signiﬁcant
differences in cortical thickness (n = 159) and FA values (n =
164) were observed compared to HC (n = 353 and 359).

Subtype-related polygenetic risk
Four PRS-SZBD scores at PT of 10−6 (NSNPs = 300), 10−5
(NSNPs = 565), 10−4 (NSNPs = 1203), and 0.001 (NSNPs =
2978) showed signiﬁcant differences between Archetypal

Identifying and validating subtypes within major psychiatric disorders based on. . .

2997

b

Heart: Atrial appendage
Heart: Left ventricle
Prostate
Pituitary
Pancreas
Thyroid
Liver
Ovary
Brain: Cerebellum
Esophagus: Muscularis
Brain: Putamen (basal ganglia)
Adrenal gland
Brain: Frontal cortex (BA9)
Muscle: Skeletal
Whole blood
Brain: Cerebellar hemisphere
Cells: Transformed fibroblasts
Brain: Hippocampus
Cells: EBV-transformed lymphocytes
Brain: Spinal cord (cervical c-1)
Adipose: Visceral (omentum)
Brain: Caudate (basal ganglia)
Brain: Hypothalamus
Minor salivary gland
Brain: Amygdala
Brain: Substantia nigra
Stomach
Colon: Sigmoid
Brain: Anterior cingulate cortex (BA24)
Spleen
Colon: Transverse
Vagina
Nerve: Tibial
Uterus
Brain: Nucleus accumbens (basal ganglia)
Artery: Coronary
Brain: Cortex
Esophagus: Muscularis
Artery: Tibial
Small intestine: Terminal ileum
Skin: Sun exposed (Lower leg)
Testis
Skin: Not sun exposed (suprapubic)
Lung
Artery: Aorta
Esophagus: Gastroesophageal junction
Fallopian tube
Adipose: Subcutaneous
Breast: Mammary tissue
Kidney: Cortex
Cervix endocervix
Bladder
Cervix ectocervix

Whole blood
Brain: Cortex
Brain: Amygdala
Brain: Putamen (basal ganglia)
Brain: Anterior cingulate cortex (BA24)
Heart: Atrial appendage
Muscle: Skeletal
Heart: Left ventricle
Brain: Nucleus accumbens (basal ganglia)
Brain: Frontal cortex (BA9)
Pancreas
Liver
Esophagus: Mucosa
Brain: Caudate (basal ganglia)
Cells: EBV-transformed lymphocytes
Brain: Hippocampus
Ovary
Stomach
Brain: Cerebellar hemisphere
Brain: Hypothalamus
Brain: Substantia nigra
Thyroid
Brain: Cerebellum
Prostate
Brain: Spinal cord (cervical c-1)
Adrenal gland
Uterus
Adipose: Visceral (omentum)
Artery: Coronary
Skin: Sun exposed (Lower leg)
Spleen
Pituitary
Nerve: Tibial
Minor salivary gland
Esophagus: Muscularis
Artery: Aorta
Adipose: Subcutaneous
Artery: Tibial
Cells: Transformed fibroblasts
Esophagus: Gastroesophageal junction
Small intestine: Terminal ileum
Skin: Not sun exposed (suprapubic)
Vagina
Colon: Sigmoid
Colon: Transverse
Kidney: Cortex
Lung
Breast: Mammary tissue
Testis
Fallopian tube
Bladder
Cervix ectocervix
Cervix endocervix

a

0

2

4

6

8

0

10

4

6

8

10

-log10 p

-log10 p

p < 0.05 in brain

2

p < 0.05

p > 0.05
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MPDs (n = 143) and HC (n = 192), explaining 5.6%,
4.9%, 4.3%, and 4.0%, respectively, of the variation in
Archetypal MPDs. The scores remained signiﬁcant after
multiple comparison correction. Compared to HC, no
signiﬁcant difference was observed in PRS-SZBD in
Atypical MPDs (n = 100) or PRS-MDD in either subtypes. The ten best-ﬁt PRS scores for each subtype are
presented in Fig. 3.

Subtype-related gene expression
Combining GWAS data and frontal cortex eQTL, we
identiﬁed 173 genes signiﬁcantly associated with Archetypal MPDs (n = 143) and 138 genes with Atypical MPD
(n = 100) (Supplementary Excel 1). These genes were then
used as input to an expression enrichment analysis on the
web-based tool, FUMA. The two sets of genes showed
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Core depressive
symptoms

Mixed symptoms

Specific somatic
depressive symptoms

un-medicated Archetypal MPDs

un-medicated Atypical MPDs

medicated Archetypal MPDs

medicated Atypical MPDs

differential expression proﬁles across 53 human tissues
from GTEx [28]. Archetypal MPDs-associated genes were
signiﬁcantly expressed in 21 tissues; about half (11 tissues)
represent brain tissues (Fig. 4a). The genes associated with
Atypical MPDs were predominantly expressed in nonbrain
tissues including the heart, prostate, pituitary, pancreas,
thyroid, and liver (Fig. 4b).
Clinical characteristics within subtypes
Medicated Archetypal MPDs had signiﬁcantly decreased
HAMD and BPRS factor scores than their unmedicated
counterpart (Fig. 5). Factors that differed signiﬁcantly were
general somatic depressive symptoms (n = 377; 95% CI,
2.24–3.58; Cohen’s d = 0.94; p < 0.001), core depressive
symptoms (n = 377; 95% CI, 2.37–4.36; Cohen’s d = 0.70;
p < 0.001), somatization (n = 377; 95% CI, 1.26–2.51;
Cohen’s d = 0.66; p < 0.001), and mixed symptoms (retardation, agitation, psychiatric anxiety, and insight) (n = 377;
95% CI, 0.52–1.17; Cohen’s d = 0.59; p < 0.001) in the
HAMD; and hostility and suspicion in the BPRS (n = 306;
95% CI, 0.52–3.13; Cohen’s d = 0.36; p = 0.007) (Fig. 5).
No signiﬁcant differences in HAMD and BPRS factor
scores were observed between medicated and unmedicated
Atypical MPDs (Fig. 5).

Biological and clinical characterization based on
clinical diagnosis
Multimodal biological characterization based on clinical
diagnosis showed continuum alterations across SZ, BD, and
MDD. The details please see Supplementary results and
Supplementary Figs. 3–7.

Discussion
In this study, we developed a novel clustering method utilizing deep learning to identify two major ALFF-based

Hostility suspicion

subtypes, Archetypal MPDs and Atypical MPDs, that differed in genetic, multimodal MRI, and clinical characteristics. Archetypal MPDs (60% of the MPDs sample) had
signiﬁcantly increased ALFF in frontal areas (prefrontal
cortex, limbic, paralimbic, and striatum) and signiﬁcantly
decreased ALFF in posterior areas (primary sensory and
motor cortices and unimodal association cortices), signiﬁcantly higher genetic vulnerability with increased PRSSZBD, enriched risk gene expression in brain regions
including the frontal cortex, limbic system, basal ganglia,
hypothalamus, cerebellum, and substantia nigra, and signiﬁcantly decreased cortical thickness and white matter
integrity in multiple brain regions, compared to HCs.
Medicated Archetypal MPDs had signiﬁcantly decreased
HAMD and BPRS factor scores than unmedicated Archetypal MPDs, suggesting the effect of medication status on
symptom severity in this subtype. In contrast, Atypical
MPDs (40%) were deﬁned by signiﬁcantly decreased ALFF
in frontal regions and signiﬁcantly increased ALFF in the
posterior brain without associated differences in PRS
scores, cortical thickness, or white matter integrity compared to HC. Risk gene expression was prominent in nonbrain tissues, such as heart, liver, pancreas, and pituitary,
which are regarded as somatic and endocrine-related tissues.
No signiﬁcant differences in HAMD and BPRS factor
scores were observed between medicated and unmedicated
Atypical MPDs, suggesting the lack of medication status
effects on symptom severity in the subtype. Collectively,
our ﬁndings implicated functional imbalance between the
frontal and posterior regions as a core and differentiating
feature across the psychotic-affective disorder continuum.
Furthermore, the subtypes, Archetypal and Atypical MPDs,
delineated by this feature were differentially associated with
genetic vulnerability, risk gene expression, cortical thickness, and white matter integrity. Interestingly, Archetypal
and Atypical MPDs were also distinct in the effects of
medication status on symptom severity, suggesting possible
differential pharmacologic effects in the two subtypes.
Additionally, multimodal biological characterization based
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on clinical diagnosis showed continuum alterations across
SZ, BD, and MDD. These ﬁndings further support that there
is a greater neurobiological overlap than previously thought
among these clinical diagnoses.
The observed ALFF pattern in Archetypal MPDs was
consistent with our prior ﬁndings of increased frontal and
decreased posterior ALFF as a shared feature across SZ,
BD, and MDD [6, 29, 30]. Signiﬁcantly increased ALFF
appeared in frontal regions including the prefrontal cortex,
limbic, paralimbic, and striatum and signiﬁcantly decreased
ALFF in the posterior primary cortices in MPDs [6].
Moreover, we also found that the ALFF ratio between these
regions in slow-4 was negatively correlated with measures
of negative and disorganized symptoms across SZ, BD, and
MDD [6]. Altogether, these ﬁndings suggest impaired balance between regions conventionally known for emotional
perception and processing and the visual cortices in MPDs.
Studies utilizing trans-diagnostic approaches are emerging [5, 6, 9, 10] as converging evidence indicates core
features across MPDs and increasing focus on the brain and
neuropsychiatric disorders from a systems perspective (i.e.,
National Institute of Mental Health Research Domain Criteria). Our ﬁndings in this study deﬁned two subtypes
across clinical diagnostic boundaries. Each clinical diagnosis, SZ, BD, or MDD, was represented in each subtype
reported herein. We also performed multimodal biological
characterization based on clinical diagnosis and found
continuum alterations across SZ, BD, and MDD (for details
regarding methods and results, see Supplementary information). Altogether, these ﬁndings further support that there
is a greater neurobiological overlap than previously thought
among the three clinical diagnoses. The mismatch between
subtypes and clinical diagnoses may in part explain frequent
inconsistent results among studies based on clinical diagnosis. The constraints of our current diagnostic system are
apparent [7, 9, 10, 31]. Reﬁning the current diagnostic
system with relevant biological measures (e.g., frontal and
posterior ALFF imbalance) would yield more biologically
homogeneous groups, which are critically important for
developing more effective and personalized treatment.
Along these lines, we developed and compared two classiﬁcation models using a 3D convolutional neural network
that categorized participants based on (1) subtypes, Archetypal and Atypical MPDs and (2) clinical diagnoses, SZ,
BD, and MDD. The accuracy and precision for the subtypebased model were signiﬁcantly higher than the model based
on clinical diagnoses, underscoring that clinical diagnoses
share more similar features and are less distinguishable from
each other in the classiﬁcation models. For full details
regarding methods and results, please see Supplementary
information and Supplementary Fig. 8.
The differences between the two subtypes, Archetypal
and Atypical MPDs, in association with PRS for BD and
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SZ, risk gene expression, cortical thickness, and white
matter integrity are of signiﬁcant interest. Compared to HC,
Archetypal MPDs had increased PRS-SZBD, indicating a
greater genetic vulnerability in this subtype. Archetypal
MPDs had enriched risk gene expression in the brain (e.g.,
frontal cortex, limbic system, basal ganglia, hypothalamus,
cerebellum, and substantia nigra), whereas Atypical MPD
had risk gene expression more prominent in somatic and
endocrine-related tissues such as the heart, liver, pancreas,
and pituitary. Signiﬁcant decreases in cortical thickness and
white matter integrity were found broadly in Archetypal
MPDs but not in Atypical MPDs. Findings in Archetypal
MPDs are consistent with previous studies of MPDs
[4, 5, 32–34]. Decreased neuronal and glial density, and
genetic and neurotransmitter alterations have been found in
multiple brain regions including the anterior cingulate cortex, dorsolateral prefrontal cortex, and nucleus accumbens
across SZ, BD, and MDD [35]. Genetic imaging studies in
SZ and BD individuals and their relatives suggest decreased
gray matter volume [32, 36] and white matter integrity
[33, 37] as potential heritable biomarkers. Altogether, our
ﬁndings support the Archetypal MPDs as a genetic and
neurodevelopmental subtype of neuropsychiatric disorders.
Further studies are needed to determine the nature of Atypical MPDs (e.g., stress-induced or stress diathesis) and
better understand the biological implications of this group.
Intriguingly, medicated Archetypal MPDs had signiﬁcantly decreased symptom severity as measured by the
HAMD and BPRS than their unmedicated counterpart but
no signiﬁcant differences in symptom severity were
observed in medicated versus unmedicated Atypical MPDs,
suggesting differential pharmacologic effects between the
subtypes. This is further supported by the ﬁndings that the
associated decreases in cortical thickness and white matter
integrity in Archetypal MPDs could represent pathological
processes that are responsive to medications [38, 39] or
direct compensatory effects of medications [40, 41].
Moreover, we found enriched risk gene expression in the
brain in Archetypal MPDs but not in Atypical MPDs. Wang
et al. previously identiﬁed a genetic proﬁle in SZ similar to
our Archetypal MPDs that consisted of brain-expressed,
high-risk genes enriched for targets of approved drugs [42].
Altogether, these ﬁndings raise questions as to whether
conventional pharmacologic treatment may be more effective in Archetypal than Atypical MPDs. Further studies are
needed to examine differences in treatment response
between the two subtypes.

Limitations
There are several limitations in this study. We used a single
biomarker (ALFF) approach in our clustering method to
identify subtypes within MPDs. There are likely other
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relevant biomarkers for clustering and subtyping, and
multimodal data could capitalize on cross-information of
the existing data [43]. Future studies are needed to identify
other relevant biomarkers and determine how best to combine different measures of multimodal brain imaging features in clustering analyses for psychiatric disorders. As
well as the potential use of the identiﬁed neuroimaging
markers for individualized prediction of clinical or cognitive measures [44]. Further, while there appears to be a
biological mechanism underlying ALFF, the exact nature of
the ALFF alterations observed herein are not clear. They
could relate to factors such as the number of prior depressive/manic/psychotic episodes. Unfortunately, we did not
collect speciﬁc data about prior illness episodes and were
not able to examine the relationship between ALFF alterations and prior depressive/manic/psychotic episodes. The
ALFF alterations could also relate to other fMRI and biological measures aside from cortical thickness and white
matter integrity. For greater biological validity and predictive utility, other biological or clinical measures should
be included in future studies of the subtypes described here.
Moreover, some studies have found that dynamic functional
features are more conducive to information related to different mental activity than static features [45]. These
cannot be measured using static parameters. Future work
should consider applying dynamic functional features to
investigate the abnormal activity. In addition, factors such
as participant inclusion criteria, the size of our clusterdiscovery data set, and the ordinal nature of our clinical
measures could have restricted our ability to identify other
subtypes.

Conclusion
In summary, our ﬁndings implicated functional imbalance
between frontal and posterior regions as a core and differentiating feature among MPDs. These ﬁndings could have
signiﬁcant contributions to the development of biologically
informed diagnostic classiﬁcations and treatment guidelines
across the psychotic-affective disorder continuum.
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